Medical treatment of brain tumours, particularly glioma, with an emphasis on novel drug evaluation for glioblastoma
Warren P Mason
Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.
Neuro Oncol. 2018 Apr 05;:
Neuro Oncol. 2018 Mar 28;:
Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.
Eur J Cancer. 2018 Mar 20;94:168-178
Oculoleptomeningeal amyloidosis secondary to the rare Transthyretin c.381T>G (p.Ile127Met) mutation.
World Neurosurg. 2017 Dec 22;:
Curr Oncol. 2017 Dec;24(6):374-382
Can J Neurol Sci. 2017 Dec 18;:1-7
CNS Oncol. 2017 Dec 15;:
Can J Neurol Sci. 2017 Nov 20;:1-6
Neuro Oncol. 2017 Sep 01;:
Hepatology. 2017 Sep 06;:
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
Medical Director, Gerry and Nancy Pencer Brain Tumour Centre
Kirchmann Family Chair in Neurooncology Research, Princess Margaret Hospital